Immunocore Holdings plc (IMCR) Current Ratio
- Current ratio · latest quarter: Value 4.47×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.47× | Current assets / current liabilities. $1.05B ÷ $235.20M ≈ 4.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.05B USD | Assets, Current |
| Current obligations | 235.20M USD | Liabilities, Current |
| Cash and equivalents | 484.92M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 395.29M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 7.79M USD | Inventory, Net |
| Payables | 26.32M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.05B | $235.20M | $484.92M | $395.29M | (m) | $7.79M | $26.32M | (m) | 4.47× |
| 2026-03-31 | $1.00B | $240.11M | $452.68M | $392.22M | (m) | $8.25M | $30.16M | (m) | 4.18× |
| 2025-12-31 | $996.74M | $246.70M | $467.71M | $396.44M | (m) | $6.74M | $24.36M | (m) | 4.04× |
| 2025-09-30 | $1.02B | $170.35M | $498.41M | $393.94M | (m) | $5.66M | $22.96M | (m) | 6.00× |
| 2025-06-30 | $1.00B | $170.08M | $487.93M | $394.88M | (m) | $5.46M | $23.86M | (m) | 5.89× |
| 2025-03-31 | $948.63M | $149.16M | $476.85M | $360.19M | (m) | $6.80M | $29.11M | (m) | 6.36× |
| 2024-12-31 | $929.86M | $212.18M | $455.73M | $364.64M | (m) | $5.45M | $25.10M | (m) | 4.38× |
| 2024-09-30 | $1.01B | $266.25M | $537.77M | $363.51M | $63.66M | $4.52M | $19.72M | (m) | 3.78× |
| 2024-06-30 | $956.86M | $185.10M | $504.99M | $354.61M | $60.24M | $3.46M | $19.95M | (m) | 5.17× |
| 2024-03-31 | $926.04M | $155.29M | $832.82M | (m) | $57.75M | $4.17M | $15.50M | (m) | 5.96× |
| 2023-12-31 | $528.82M | $139.02M | $442.63M | $0.00 | $52.09M | $4.50M | $17.80M | (m) | 3.80× |
| 2022-12-31 | $473.98M | $100.83M | $402.47M | (m) | $33.58M | $692.00K | $14.45M | (m) | 4.70× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |